Latanoprost is an eye drop formulation helpful in the management of elevated intraocular pressure (IOP) within patients grappling with ocular hypertension or open-angle glaucoma. This prostaglandin F2 alpha analog is a frontline approach in glaucoma treatment, leveraging its proven efficacy in IOP reduction. Renowned for its convenience with a once-daily dosing regimen and an acceptable safety profile, prostaglandins like latanoprost have become the cornerstone of glaucoma therapy.The United States Food and Drug Administration (FDA) approved the fixed-dose combination of netarsudil/latanoprost in March 2019, expanding treatment options for those afflicted with open-angle glaucoma and ocular hypertension. Beyond its approved applications, latanoprost is utilized off-label for diverse glaucoma variants. This activity covers latanoprost’s mechanism of action, pharmacology, indications, adverse event profiles, contraindications, toxicity, and the collaborative efforts of the interprofessional team essential in managing conditions where latanoprost proves therapeutically beneficial.
- Provider:StatPearls, LLC
- Activity Link: https://www.statpearls.com/ArticleLibrary/viewarticle/37245
- Start Date: 2023-09-01 05:00:00
- End Date: 2023-09-01 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
ABPATH - 1.0 Point; Credit Type(s): Lifelong Learning (ABPATH)
ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
ABS - 1.0 Point; Credit Type(s): Self-Assessment (ABS) - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: All Practice Areas (e.g. ethics), General Surgery, Geriatric Medicine, Internal Medicine